RGEN
Repligen Corporation
NASDAQ: RGEN · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES
$113.11
-3.68% today
Updated 2026-04-29
Market cap
$6.38B
P/E ratio
131.52
P/S ratio
8.64x
EPS (TTM)
$0.86
Dividend yield
—
52W range
$110 – $176
Volume
0.9M
WallStSmart proprietary scores
45
out of 100
Grade: C
Sell
Investment rating
6.7
Growth
B7.8
Quality
B+4.5
Profitability
C3.3
Valuation
D6/9
Piotroski F-Score
Moderate
2.3
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$179.78
+58.94%
12-Month target
$40.25
-64.42%
Intrinsic (DCF)
$160.09
Margin of safety
+12.92%
3 Strong Buy13 Buy4 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $17.05M — positive
+ Revenue growth 18.10% QoQ
+ 12.92% below intrinsic value
Risks
- P/E 131.52x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $801.54M | $638.76M | $634.44M | $738.26M | $738.26M |
| Net income | $185.96M | $41.58M | $-25.51M | $48.89M | $13.29M |
| EPS | — | — | — | — | $0.86 |
| Free cash flow | $38.74M | $74.93M | $142.49M | $93.90M | $17.05M |
| Profit margin | 23.20% | 6.51% | -4.02% | 6.62% | 6.62% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-05 | LOEILLOT, OLIVIER | Buy | 25,890 | — |
| 2026-03-05 | LOEILLOT, OLIVIER | Buy | 24,134 | — |
| 2026-03-05 | KURIYEL, RALF | Buy | 5,669 | — |
Peer comparison
Smart narrative
Repligen Corporation trades at $113.11. representing a P/E of 131.52x trailing earnings. Our Smart Value Score of 45/100 indicates the stock is fair. The company scores 6/9 on the Piotroski F-Score. With an Altman Z-Score of 2.34, it sits in the grey zone. TTM revenue stands at $738.26M. with profit margins at 6.62%. Our DCF model estimates intrinsic value at $160.09.
Frequently asked questions
What is Repligen Corporation's stock price?
Repligen Corporation (RGEN) trades at $113.11.
Is Repligen Corporation overvalued?
Smart Value Score 45/100 (Grade C, Sell). DCF value $160.09.
What is the price target of Repligen Corporation (RGEN)?
The analyst target price is $179.78, representing +58.9% upside from the current price of $113.11.
What is the intrinsic value of Repligen Corporation (RGEN)?
Based on our DCF model, intrinsic value is $160.09, a +12.9% margin of safety versus $113.11.
What is Repligen Corporation's revenue?
TTM revenue is $738.26M.
Piotroski F-Score?
6/9 — moderate financial health.
Altman Z-Score?
2.34 — grey zone.
Company info
SectorHEALTHCARE
IndustryMEDICAL INSTRUMENTS & SUPPLIES
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio8.64x
ROE2.40%
Beta1.19
50D MA$122.34
200D MA$138.06
Shares out0.06B
Float0.05B
Short ratio—
Avg volume0.9M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—